PharmaGap Inc.  

(Public, CVE:GAP)   Watch this stock  
Find more results for pharmagap'
0.005
Apr 18 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.00 - 0.00
Open     -
Vol / Avg. 0.00/0.00
Mkt cap 728,145.00
P/E     -
Div/yield     -
EPS -0.02
Shares     -
Beta 0.58
Inst. own     -

Key stats and ratios

Q3 (Sep '12) 2011
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -816.54% -810.47%
Return on average equity - -
CDP Score - -

Address

100 Sussex Drive
Ottawa, ON K1A 0R6
Canada
+1-613-9983400 (Phone)
+1-613-9983399 (Fax)

Website links

Description

PharmaGap Inc. is a Canada-based biotechnology company. The Company focuses on developing peptide therapeutics for the treatment of cancer. PharmaGap�s GAP-107B8 is a peptide drug that has been shown to be effective in numerous cancer types, including chemo-resistant cancers, in vitro.

Officers and directors

Roderick M. Bryden Chairman of the Board
Age: 72
Robert C. McInnis President, Chief Executive Officer
Gerald Leahy Chief Financial Officer
Kenneth K. Sokoll Ph.D. Chief Operating Officer
Jenny Phipps Chief Scientific Officer, Director
Daniel B. Larkin Independent Director
Robert Letellier Independent Director
Ian W. Malone Independent Director